Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00190580
Status:
COMPLETED
Last Update Posted:
2015-03-31
First Post:
2005-09-11
Brief Title:
Kanagawa Valsartan Trial KVT Effects of Valsartan on Renal and Cardiovascular Disease
Sponsor:
KVT-Study Group
Organization:
KVT-Study Group
Study Overview
Official Title:
Effects of Valsartan on the Progression of Renal and Cardiovascular Disease - Kanagawa Valsartan Trial KVT
Status:
COMPLETED
Status Verified Date:
2009-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to prove the hypothesis that the progression of renal and cardiovascular disease is more efficiently prevented when the angiotensin II receptor blocker valsartan is added to conventional antihypertensive therapy
Detailed Description:
It is widely recognized that suppression of the renin-angiotensin system ameliorates progression of chronic kidney disease CKD and that CKD is an important risk factor for development of cardiovascular disease However it has not been fully clarified if amelioration of CKD leads to the lower incidence of cardiovascular disease The purpose of this study is to determine whether the angiotensin II receptor antagonist valsartan in combination with conventional antihypertensive therapy will ameliorate progression of both CKD and cardiovascular disease The primary outcome is courses of renal and cardiac function The secondary outcome is a composite of a doubling of serum creatinine concentration end-stage renal disease myocardial infarction coronary revascularization stroke hospitalization for unstable angina hospitalization for heart failure or death from cardiovascular causes
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None